

14th International Conference on

Clinical Gastroenterology and Hepatology

August 29-30, 2018 | Toronto, Canada

Can use Golgi protein 73(GP73), as a serum biomarker for early surveillance of hepatocellular carcinoma in the first stage and chronic liver diseases in Saudi Arabia patients

Randa Mohamed MA Farag¹, Dujana AlAyobi, Hye-Joo Kwon, Khalid A Alsaleh², Afaf EL-Ansary and Emad A Dawoud³

¹Princess Nourah Bint Abdulrahman University, Kingdom Saudi Arabia

²King Saud University, Kingdom Saudi Arabia

³EL-Azher University and Tawam Hospital, UAE

This study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with liver disease, and to evaluate the correlations between GP73 and other serum markers in different liver diseases. Study the sensitivity and specificity of Golgi Glypican-73 (GP37) as new biomarker useful in early prediction for Hepatocellular Carcinoma in hepatitis viruses (HBV, HCV) and in chronic liver Cirrhosis; Also in chronic liver diseases. Serum GP73 was measured in 478 healthy controls and 296 patients with different types of liver disease. Quantitative hepatitis B virus (HBV) DNA was determined in two chronic hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured in the liver fibrosis group and α -fetoprotein (AFP) was measured in hepatocellular carcinoma (HCC) group. The correlations between GP73 and these markers were evaluated. The GP73 value in hepatitis B-e-antigen (HBeAg)-positive CHB group, HBeAg-negative CHB group, liver fibrosis group and HCC group was significantly higher ($p < 0.001$) than that in healthy controls. GP73 showed significant correlation with other markers in the liver fibrosis group and with AFP in the HCC group. Compared with healthy controls, GP73 in patients with liver disease was significantly increased. With the progression of liver disease, GP73 showed a significantly increasing trend. These results suggest that GP73 might be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progression

randa792006@gmail.com